Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation.
Silbermann RW, Schmidt TM, Bal S, Dhakal B, Dholaria B, Biltibo E, Chhabra S, Giri S, Godby KN, Gowda S, Medvedova E, Cornell RF, Callander NS, Costa LJ. Silbermann RW, et al. Among authors: dhakal b. EJHaem. 2023 Jun 22;4(3):775-778. doi: 10.1002/jha2.736. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601885 Free PMC article.
Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Badar T, et al. Among authors: dhakal b. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213. doi: 10.1038/s41409-018-0178-5. Epub 2018 Apr 20. Bone Marrow Transplant. 2018. PMID: 29679076 No abstract available.
Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis.
D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P. D'Souza A, et al. Among authors: dhakal b. Contemp Clin Trials Commun. 2017 Aug 24;8:33-38. doi: 10.1016/j.conctc.2017.08.012. eCollection 2017 Dec. Contemp Clin Trials Commun. 2017. PMID: 29696194 Free PMC article.
Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation.
Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Knight JM, et al. Among authors: dhakal b. BMC Cancer. 2018 May 24;18(1):593. doi: 10.1186/s12885-018-4509-0. BMC Cancer. 2018. PMID: 29793446 Free PMC article. Clinical Trial.
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Guru Murthy GS, et al. Among authors: dhakal b. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. doi: 10.1016/j.bbmt.2018.12.069. Epub 2018 Dec 18. Biol Blood Marrow Transplant. 2019. PMID: 30572109 Free article.
266 results